BIO-RAD LABORATORIES, INC.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Income (Loss)

(In millions, except number of shares, which are reflected in thousands, and per share data)

(Unaudited)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2026	2025	2026	2025
Net sales	$656.4	$653.0	$1,899.5	$1,890.0
Cost of goods sold	327.8	309.6	915.7	895.3
Gross profit	328.6	343.4	983.8	994.7
Selling, general and administrative expense	257.1	206.8	681.5	623.3
Research and development expense	71.4	71.3	195.5	205.3
Impairment of purchased intangibles	49.8	—	49.8	—
Income (loss) from operations	(49.7)	65.3	57.0	166.1
Interest expense	12.3	12.3	36.7	36.9
Foreign currency exchange gains, net	(2.1)	(2.9)	(4.7)	(4.5)
(Gains) losses from change in fair market value of equity securities and loan receivable	(588.2)	495.3	(308.0)	129.1
Other income, net	(10.4)	(8.3)	(58.0)	(61.7)
Income (loss) before income taxes	538.7	(431.1)	391.0	66.3
(Provision for) benefit from income taxes	(80.1)	89.2	(88.1)	(26.4)
Net income (loss)	$458.6	$(341.9)	$302.9	$39.9
Basic earnings (loss) per share:
Net income (loss) per basic share	$17.13	$(12.70)	$11.29	$1.46
Weighted average common shares - basic	26,780	26,923	26,827	27,359
Diluted earnings (loss) per share:
Net income (loss) per diluted share	$17.02	$(12.70)	$11.25	$1.46
Weighted average common shares - diluted	26,945	26,923	26,923	27,369

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.